Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial (2018)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1016/j.ahj.2018.02.017
- Subjects: FÁRMACOS (SISTEMA CARDIOVASCULAR); INFARTO DO MIOCÁRDIO; SÍNDROME CORONARIANA AGUDA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: American heart journal
- ISSN: 0002-8703
- Volume/Número/Paginação/Ano: v. 202, p. 89-96, 2018
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
BERWANGER, Otavio e NICOLAU, José Carlos. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial. American heart journal, v. 202, p. 89-96, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2018.02.017. Acesso em: 25 jan. 2026. -
APA
Berwanger, O., & Nicolau, J. C. (2018). Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial. American heart journal, 202, 89-96. doi:10.1016/j.ahj.2018.02.017 -
NLM
Berwanger O, Nicolau JC. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial [Internet]. American heart journal. 2018 ; 202 89-96.[citado 2026 jan. 25 ] Available from: https://doi.org/10.1016/j.ahj.2018.02.017 -
Vancouver
Berwanger O, Nicolau JC. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial [Internet]. American heart journal. 2018 ; 202 89-96.[citado 2026 jan. 25 ] Available from: https://doi.org/10.1016/j.ahj.2018.02.017 - P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes
- Impact of the Extent of Coronary and Myocardial Disease on the Treatment Effect of Surgical Revascularization in Patients With Ischemic Left Ventricular Dysfunction
- Doença arterial coronariana aguda
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
- Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease
- Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
Informações sobre o DOI: 10.1016/j.ahj.2018.02.017 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
